

Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



14th August, 2018

To,

Corporate Relation Department
BSE Ltd
1st Floor, New Trade Wing,
Rotunda Building, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

**National Stock Exchange of India
Limited**

“Exchange Plaza”, C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 05

Scrip Code: 532637

Symbol: MANGALAM

Sub: Un-audited Financial Results for the Quarter ended on 30th June, 2018

Dear Sir,

In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith Un-audited Financial Results for the quarter ended 30th June, 2018 along with Limited Review Report of the said period in the prescribed form which have been taken on record and approved by the Board of Directors of the company in its meeting held today i.e. 14th August, 2018 at Mumbai.

Kindly note that meeting of Board of Directors commenced at 12.00 P.M. and concluded at 03.40 p.m.

Further please note that the company has made necessary arrangement to publish the same in newspapers as required under Listing Regulations.

Kindly acknowledge the receipt and take the same on your records.

Thanking You,

Yours faithfully,

For **Mangalam Drugs & Organics Ltd**

Nikita Bavishi



Nikita Bavishi
Company Secretary



Works: at Vapi (Gujarat) India • E-Mail : contactus@mangalamdrugs.com • Website : <http://www.mangalamdrugs.com>

Un-Audited Financial Results for the Quarter Ended 30th June 2018 approved and taken on record by the Board at their meeting dated 14th August, 2018

Sr.No	Particulars	Rs. in Lacs			
		Quarter Ended		Year Ended	
		30.06.2018 Unaudited	31.03.2018 Audited	30.06.2017 Unaudited	31.03.2018 Audited
A) Part-1 Statement of Un-Audited Financial Results for the Quarter Ended June 30, 2018					
1	Revenue from Operations	5,900.71	6,719.50	5,513.65	27,937.96
2	Other Income	2.77	10.26	4.41	82.70
3	Total Revenue(1+2)	5,903.48	6,729.76	5,518.06	28,020.66
4	Expenses				
	(a) Cost of Materials Consumed	3,710.56	4,044.52	3,971.56	18,047.91
	(b) Employee Benefits Expense	653.90	597.12	548.99	2,298.37
	(c) Changes in Inventories, Finished Goods and Stock-in-trade	85.11	18.76	(1,405.96)	(1,711.73)
	(d) Finance Costs	208.15	342.92	249.84	1,178.00
	(e) Depreciation	178.19	257.78	125.32	656.82
	(f) Other Expenses	964.85	1,107.97	1,412.52	4,616.57
	(g) Total Expenses	5,800.76	6,369.07	4,902.27	25,085.94
5	Profit / (Loss) before exceptional & extraordinary items and tax(3-4)	102.72	360.69	615.79	2,934.72
6	Exceptional items	0.00	0.00	0.00	0.00
7	Profit/(Loss) before extraordinary items and tax (5-6)	102.72	360.69	615.79	2,934.72
8	Extraordinary Items	0.00	0.00	0.00	0.00
9	Profit(+)/Loss (-) before tax(7-8)	102.72	360.69	615.79	2,934.72
10	Tax Expenses	35.89	55.15	200.19	945.76
11	Net Profit(+)/Loss(-) after Tax (9-10)	66.83	305.54	415.60	1,988.96
12	Other Comprehensive income not reclassified into Profit & loss account (Net of Taxes)	0.42	(34.72)	2.57	36.32
13	Total Comprehensive Income	67.25	270.82	418.17	2,025.28
14	Paid-up Equity Share Capital (face value of Rs 10/- each)	1,582.82	1,582.82	1,582.82	1,582.82
15	Other Equity				8,935.43
16	Earnings Per Share (EPS) (of Rs 10/-each)not annualised):				
	(a) Basic	0.42	1.93	2.63	12.57
	(b) Diluted	0.42	1.93	2.63	12.57

Notes :

- The above results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on August 14, 2018. The Statutory Auditors have carried out a limited review of the results.
- As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments".
- W.e.f April 1, 2018, the Company has adopted Ind AS 115 – "Revenue from contracts with customers" under the full retrospective approach. Accordingly, the comparatives have been adjusted to give the effect of Ind AS 115. The effect on adoption of Ind AS 115 was insignificant on the financial results.
- Earlier period figures have been regrouped/ rearranged wherever necessary.

Place: Mumbai
Date: 14th August, 2018

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)
Chairman & Managing Director
(DIN:01240086)



Review Report on Quarterly Financial Results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,

The Board of Directors,
Mangalam Drugs and Organics Limited.
Mumbai

1. We have reviewed the accompanying statement of unaudited financial results of Mangalam Drugs and Organics Limited. ("the Company") for the quarter ended 30th June, 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. This statement has been compiled from the financial statements which has been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to the financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards as notified under the Companies (Indian Accounting Standards) Rules, 2015 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.



BRANCHES :

NAVI MUMBAI : 302 / 304 Arenja Corner, Sector 17, Vashi, Navi Mumbai - 400 703. • Tel. : +91-22-2766 6478
DELHI : 505, Nirmal Tower, 26, Barkhamba Road, New Delhi -110 001. • Tel. : +91-11-4019 0200

4. The Comparative financial information of the Company for the corresponding quarter ended June 30th 2018, included in these financial results, were reviewed by the predecessor auditor who expressed an unmodified opinion/conclusion on those financial information/results on 11th August 2017.

For Batliboi & Purohit
Chartered Accountants
FRN No.: 101048W



CA Raman Hangekar
Partner
Membership No.: 030615

Place : Mumbai
Date : 14th August 2018

